Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C40B 20/08 - Direct analysis of the library members per se by physical methods, e.g. spectroscopy

Abstract

The present invention relates to a polypeptide for use as a metal-binder, a protein comprising said polypeptide, a nucleic acid molecule encoding said polypeptide or protein, an expression vector comprising the nucleic acid molecule, a recombinant host cell comprising said polypeptide, protein, nucleic acid molecule and/or expression vector, a pharmaceutical composition comprising the said polypeptide, protein, nucleic acid molecule, expression vector and/or host cell, and to a kit.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A61K 51/08 - Peptides, e.g. proteins

Abstract

An isolated immune cell, a method for preparing such modified immune cell, a method of treating a living being suffering or at risk of suffering from cancer or non-malignant diseases, an oligonucleotide and a use thereof.

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to chemically modified oligonucleotides comprising a sequence with a length of 23 to 80 nucleotides, capable of binding to a target sequence in a target RNA, comprising a central base triplet (CBT) of 3 nucleotides (5′—N−1eN0fN+1g-3′) with the central nucleotide (N0) directly opposite to the target adenosine in the target RNA, wherein the core oligonucleotide comprises the following sequence: 5′—N−5aN−4b N−3cN−2dN−1eN0fN+1gN+2h N+3 iN+4j-3′ comprising different 2′ sugar and linkage modifications. The present disclosure also provides oligonucleotides and compositions thereof for use in use in the treatment or prevention of a genetic disorder, condition, or disease. Also provided are methods for editing a target adenosine or deaminating at least one specific adenosine in a target nucleic acid.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to a process for esterifying cyanophycin with various alcohols, to esterified cyanophycin, and to various uses and compositions of the processes and products described in the invention.

IPC Classes  ?

• C08G 69/46 - Post-polymerisation treatment
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• C09D 177/02 - Polyamides derived from omega-amino carboxylic acids or from lactams thereof
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of oropharyngeal squamous cell carcinoma (OPSCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides novel human fms related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and/or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3xCD3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/46 - Hybrid immunoglobulins

Abstract

The present invention provides an artificial nucleic acid for site-directed editing of a target RNA with enhanced editing specificity and avoiding undesirable off-target editing. The artificial nucleic acid comprises a targeting sequence comprising a nucleic acid sequence complementary to or at least partially complementary to a target sequence in the target RNA comprising one or more nucleotides to be edited, wherein the targeting sequence is flanked by a first recruiting moiety capable of recruiting a deaminase, and a second recruiting moiety capable of recruiting a deaminase, wherein at least one of the first and second recruiting moiety comprises at least one recruitment sequence, and preferably comprises at least two recruitment sequences, which bind(s) to complementary region(s) in the target RNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention is directed to a gene editing system for editing genomic DNA to modulate splicing, a polynucleotide or vector encoding said gene editing system, a lipid particle comprising said gene editing system, a pharmaceutical composition comprising said gene editing system polynucleotide or vector or lipid particle, methods of editing genomic DNA in a cell to modulate splicing, and a cell processed by said methods.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A microfluidic device, a microfluidic system comprising said microfluidic device, and to a method of culturing biological material.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The present invention relates to a chemically modified oligoribonucleotide for use in site-directed A-to-1 editing of a target RNA inside a cell with endogenous ADAR, comprising a sequence with a length from 25 to 80 nucleotides, capable of binding to a target sequence in the target RNA, comprising a Central Base Triplet of 3 nucleotides with the central nucleotide opposite to the target adenosine in the target RNA which is to be edited to an inosine, having a) at least 90% of the pyrimidine nucleosides outside the Central Base Triplet are chemically modified, either at the 2′ position of the sugar moiety or as deoxyribonucleosides, or a combination thereof, b) no more than 6 consecutive nucleosides are chemically modified with 2′-O-methyl at the 2′ position of the sugar moiety, c) at least two of the three nucleosides of the Central Base Triplet are chemically modified at the 2′ position of the sugar moiety, or are deoxyribonucleosides,

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a method for making a genetic determination based on a hair root sample, a kit adapted for carrying out said method, and to a use of a hair root sample from a test individual for making a genetic determination.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6869 - Methods for sequencing

Abstract

The invention relates to a novel compound for the treatment and prophylaxis of a disease, especially a bacterial infectious disease, for reducing pathogen virulence and promoting host-induced clearance of infection and/or sensitizing bacteria to antibiotic treatment, a method for preparing said compound, a pharmaceutical composition comprising said compound, and to a method for the treatment and/or prophylaxis of a disease, preferably a bacterial infectious disease.

IPC Classes  ?

• C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to peptides, antigen binding proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, especially of fibrolamellar hepatocellular carcinoma (FL-HCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes and recombinant T-cell receptors that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A system for performing quantum operations comprising an optical superlattice and a plurality of optical tweezers, wherein the optical superlattice comprises a plurality of main sites; each main site comprises a storage site and an auxiliary site, each configured to hold an atom; the optical superlattice is configured to merge the storage site and the auxiliary site of each main site; and the plurality of optical tweezers is configured to move atoms provided in the plurality of main site from one main site to another main site.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present invention relates to a compound for the inhibition of the transmission of malaria in humans, a pharmaceutical composition comprising said compound, and a method for the inhibition of the transmission of malaria in humans comprising the administration of said compound.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/65 - Tetracyclines
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to a method for producing a surface which can be colonized with biological cells, a device having a surface which can be colonized with biological cells, and a method for colonizing a surface with biological cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 11/06 - Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent

Abstract

The present invention relates to a surgical device for clamping in tissue, wherein the surgical device comprises a first clamp, a second clamp, and an elongated dimensionally stable connector and its use within a minimally invasive or open surgical treatment for effecting tissue to be self-hold.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present invention relates to a nucleic acid molecule for an allele-specific editing of the ELANE gene, a vector comprising said nucleic acid molecule, a composition comprising said nucleic acid molecule or vector, a method in vitro for an allele-specific editing the ELENE gene in biological material including genetic material encoding said ELENE gene, and to a method for the prophylaxis and/or treatment and/or examination of a disease in a living being.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein interaction of AURKA with binding proteins, such as MYC and/or TPX2. The present invention also pertains to the use of such compounds in the prevention and/or treatment of proliferative diseases, such as cancer, and kits comprising the same.

IPC Classes  ?

• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 35/00 - Antineoplastic agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention relates to a method for diagnosing a predisposition of a living being to develop thrombocytopenia, and uses associated therewith.

IPC Classes  ?

• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus

Abstract

The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased munogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus vector and/or said cell, and a new use of said modified Parapoxvirus.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 39/275 - Poxviridae, e.g. avipoxvirus
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus

Abstract

The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased immunogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus and/or said cell, and a new use of said modified Parapoxvirus.

IPC Classes  ?

• A61K 39/275 - Poxviridae, e.g. avipoxvirus
• C12N 15/86 - Viral vectors
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• A61P 35/00 - Antineoplastic agents

Abstract

A composition is for the targeted knockout of a gene on double-stranded DNA in a biological cell. A method is for the targeted knockout of a gene on double-stranded DNA in a biological cell. A preparation includes a biological cell prepared in vitro. The biological cell includes a gene on double-stranded DNA, which is knocked-out in a targeted manner. A kit is for the targeted knockout of a gene on double-stranded DNA in a biological cell. Another method is for treating a subject afflicted with a disease associated with a mutated gene. Nucleic acid molecules can be a component of the composition and methods.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 37/02 - Immunomodulators

Abstract

SARS-CoV2-associated T-cell peptide epitopes as active pharmaceutical ingredients of vaccine compositions to stimulate anti-SARS-CoV2 immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides of SARS-CoV2-associated T-cell peptide epitopes bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of an infection by SARS-CoV-2 (COVID-19). The present invention furthermore relates to SARS-CoV-2-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-SARS-CoV-2 immune responses, or to stimulate T-cells ex vivo and transfer them into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/725 - T-cell receptors
• C07K 14/74 - Major histocompatibility complex [MHC]
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four α-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming α-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoiesis and/or for use in mobilizing hematopoietic stem cells.

IPC Classes  ?

• C07K 14/535 - Granulocyte CSFGranulocyte-macrophage CSF
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

The invention is based on a method of modulating the activation or inhibition of Mixed lineage kinase domain-like (MLKL) protein, or a MLKL variant protein, via modulating the intramolecular interaction between the C-terminal helix (Hc) of the psK domain and a hydrophobic groove in the MLKL protein. The invention provides methods and compounds for to selectively target the herein firstly disclosed intramolecular interaction of MLKL protein. Based on the herein disclosed essential intramolecular rearrangement of MLKL, the invention provides small molecules capable of specifically inhibiting mouse or human MLKL. The invention provides uses, including medical applications such as treatments, of MLKL driven conditions including necroptosis, cell trafficking, pathological immune responses and/or inflammation.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/47 - QuinolinesIsoquinolines
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a novel agent for the prophylactic and therapeutic treatment of a coronavirus infection and/or a disease caused by said infection, a pharmaceutical composition containing said agent, and a method for the prophylactic and/or therapeutic treatment of a coronavirus infection and/or a disease caused by said infection.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 31/14 - Antivirals for RNA viruses

Goods & Services

Electronic muscle and nerve stimulators for medical uses; electronic nerve and muscle stimulation apparatus for the therapeutic treatment of pain; apparatus for electrical stimulation of nerves and muscles for pain management purposes Scientific and technological services and research relating thereto in the field of pain, namely, testing of various stimulation methods through pain probes for the treatment of pain; clinical research consulting on research and development in the field of therapeutic methods, in particular in the field of pain Provision of information in the field of medicine, namely, providing medical information relating to pain and to the diagnosis and treatment of pain; providing online information in the field medicine, namely, providing information relating to pain and to the diagnosis and treatment of pain via the internet; medical services in the field of treatment of chronic pain; conducting electronic stimulation therapies for the treatment of pain; performing of surgical treatment services, namely, performing minimally invasive surgical procedures for the implantation of probes in the spinal canal for pain treatment; medical testing for treatment purposes through pain probes in the field of pain conditions

Abstract

The present invention relates to a medical device for generating a plasma-activated liquid, a system for generating plasma-activated liquids comprising said device, and a method for generating a plasma-activated liquid. It also relates to a method for prophylaxis and treatment of postoperative adhesions.

IPC Classes  ?

• A61N 1/44 - Applying ionised fluids
• H05H 1/24 - Generating plasma

Abstract

The present invention relates to relates to T cell epitope peptides, proteins, nucleic acids and cells for use in immunother-apeutic methods. In particular, the present invention relates to the immunotherapy of viral infection. The present invention specifically relates to virus-associated T-cell peptide epitopes, alone or in combination with other virus-associated peptides that can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-viral immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/25 - Varicella-zoster virus

Abstract

The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention relates to a method ex vivo for classifying a patient in need as non-responder or responder to immune checkpoint inhibitor therapy, and the use of a gene set for classifying a patient in need as non-responder or responder to immune checkpoint inhibitor therapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to new peptides the amino acid sequences of which are derived from HD-5, for use in the treatment and/or prevention of Herpesviridae infections, in particular for treating and/or preventing a Betaherpesviridae infection, such as a HCMV-infection.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 31/20 - Antivirals for DNA viruses

Abstract

A gas sensor that selectively detects and/or measures acetylene and/or ethylene includes a substrate; at least one electrode pair; at least one gas-sensitive layer consisting of at least one metal oxide from the group ReFeO3 and in contact with the at least one electrode pair; a heating element; and at least one control device, wherein the heating element is adapted to be heated alternately to at least two different temperatures of 150° C.-250° C., 200° C.-300° C. and 250° C.350° C., respectively, by the control device.

IPC Classes  ?

• G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

A pharmaceutical composition is for prophylaxis and/or treatment of an infection of the cervix with human papillomavirus (HPV). A method carried out ex vivo is for predicting the probability of cure of HPV infection of the cervix. A biomarker is for predicting the emergence and/or development of cervical in-traepithelial neoplasia and/or cervical carcinoma and the likelihood of cure of cervical infection with HPV. Another method is for prophylaxis and/or treatment of cervical infection with HPV.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-αβ-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) to reduce αβ T cells in the subject relative to γδ T cells in the subject are provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a compound for use in the treatment or prevention of a liver disease, wherein the compound is a amyloid beta related protein, the amyloid beta related protein being selected from the group consisting of amyloid beta protein, a amyloid beta peptide derived therefrom, amyloid precursor protein (APP), a compound involved in the generation of an amyloid beta peptide from APP, or a compound inhibiting the degradation of the amyloid beta protein or of amyloid peptides derived therefrom.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

3 antigen binding protein (ABP) of the invention.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/46 - Hybrid immunoglobulins

Abstract

A spacer for an endodontic instrument includes a base surface with a diameter dG, a top surface with a diameter dD, which is smaller than the diameter dG, an axis of rotation, a lateral surface, a height h, an opening with a longitudinal axis for receiving an endodontic instrument and a cylindrical recess for receiving a stopper on the base surface. The spacer is frustoconically formed, and the opening extends from the base surface to the top surface. The longitudinal axis of the opening is coaxial to the axis of rotation of the spacer, and the cylindrical recess is coaxial to the opening.

IPC Classes  ?

• A61C 5/44 - Means for controlling working depth, e.g. supports or boxes with depth-gauging means, stop positioners or files with adjustably-mounted handles

Abstract

The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.

IPC Classes  ?

• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• C07H 7/02 - Acyclic radicals
• C07H 9/02 - Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms

Abstract

The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array compris¬ ing capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

A method is used for determining a status of an encapsulation and/or a passivation layer of the encapsulation. The encapsulation forms a multi-layer system from multiple passivation layers arranged on top of one another and electrically contacted intermediate layers arranged between the passivation layers. The multi-layer system protects an implant surrounded by the encapsulation. In the method, an electrical measurement is carried out between a reference potential and at least one electrically contacted intermediate layer, and at least one current flowing between the reference potential and the at least one electrically contacted intermediate layer is detected. The at least one detected current is compared with at least one pre-determined threshold value. If the detected current falls below or exceeds the at least one threshold value, this indicates a functional state of a passivation layer adjacent to the at least one electrically contacted intermediate layer.

IPC Classes  ?

• G01M 3/16 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using electric detection means

Abstract

The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/785 - Alveolar surfactant peptidesPulmonary surfactant peptides

Abstract

The invention relates to methods and substances for the targeted alteration of genetic information on an RNA level. The substances are artificially produced guide RNAs, which are capable of recruiting endogenous editing enzymes, such as hADAR enzymes, in particular hADAR2 and hADAR1, in order to introduce targeted point mutations in selected mRNAs. The guide RNA consists of multiple segments and is constructed in such a way that individual nucleotides from different segments pair to form a double helix, and the nucleotides of a determined segment form a hairpin structure within the guide RNA. The invention also relates to the method for directed RNA editing, wherein the guide RNA is transfected into the cells in which the RNA editing is to be carried out. The substances and the method can be used for repairing individual, e.g. disease-relevant point mutations, such as those leading to premature stop signals. An advantage of the invention is that endogenous editing enzymes are also used in order to introduce targeted point mutations into the RNA. Only the short guide RNA, used for recruiting endogenous editing enzymes, must be artificially produced for each specific problem and ectopically expressed.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

In a method for examining the faculty of hearing for at least one ear of a mammal, in which growth curves are determined on the basis of the measurement of DPOAE's evoked by pairs of excitation signals (f1, f2) for different excitation frequencies f2, the ear is presented with first excitation signals with a first excitation frequency f1 and a first noise level L1 and secondary excitation signals with a second excitation frequency f2 and a second noise level L2. Pulse pairs with a first pulse of the first excitation signal and a second pulse of the second excitation signal are presented in the ear, and the DPOAE's evoked thereby are captured and evaluated. A set of at least two different pulse pairs with different second excitation frequencies f2 is presented in one block that is repeated several times during a measuring period.

IPC Classes  ?

• A61B 5/12 - Audiometering
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/557 - Eicosanoids, e.g. leukotrienes
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

In a hearing aid (26) that can be inserted into the ear canal (12) of a patient, comprising an actuator (31) effecting a mechanical stimulation of the tympanic membrane (14), the actuator (31) comprises an inner surface (32) associated with the tympanic membrane (14) and an outer surface (42) associated with the ear canal (12) and is configured as an areal disk actuator, whose deformation stimulates the tympanic membrane (14) by areal deformation. On the actuator (31) at a distance from the outer surface (42) a cover plate (43) is arranged which together with the outer surface (42) delimits a preferably lenticular cavity (48).

IPC Classes  ?

• H04R 25/00 - Deaf-aid sets
• H04R 17/00 - Piezoelectric transducersElectrostrictive transducers

Abstract

The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-αβ-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibodies and/or fragments thereof) to reduce αβ T cells in the subject relative to γδ cells in the subject are provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• C12N 5/079 - Neural cells
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells